APC-derived cytokines and T cell polarization in autoimmune inflammation

Ilona Gutcher and Burkhard Becher

Neuroimmunology Unit, Neurology Clinic, University of Zurich, Zurich, Switzerland.

T cell–mediated autoimmune diseases such as multiple sclerosis and rheumatoid arthritis are driven by autoaggressive Th cells. The pathogenicity of such Th cells has, in the past, been considered to be dictated by their cytokine polarization profile. The polarization of such effector T cells relies critically upon the actions of cytokines secreted by APCs. While Th1 polarization has long been associated with the pathogenesis of autoimmune diseases, recent data obtained in gene-targeted mice and the discovery of Th17 cell involvement in autoimmunity conflict with this hypothesis. In light of these recent developments, we discuss in this review the actions of APC-derived cytokines and their emerging roles in T cell polarization in the context of autoimmune inflammatory responses.

The Th1/Th2 paradigm of autoimmunity

In 1986 Mosmann et al. initially proposed a model whereby CD4+ T cells are subdivided into two independent subsets with distinct effector functions (2, 3). Their hypothesis suggested that Th cells can be segregated into Th1 and Th2 subsets on the basis of cytokine expression and bioactivities as well as helper function. Those and further experiments demonstrated that Th1 cells secrete predominantly IL-2, IL-3, TNF-α, and most notably IFN-γ and control cell-mediated functions such as the activation of macrophages, while the secretion of IL-4, IL-5, and IL-13 by Th2 cells leads to the stimulation of humoral immunity by aiding B cell activation and class switching (3). Interestingly, the cytokines of a particular Th subtype are able to further promote the expansion of that subtype population while simultaneously inhibiting the development of the other subset. This allows each Th subset to produce characteristic cytokines that in turn provoke the development of a distinctive effector function specific for that immunogen. Thus, while Th1 cells induce proinflammatory responses, such as delayed-type hypersensitivity, and eliminate intracellular infections, Th2 cells mediate allergic reactions and anti-helminth responses (1).

The differentiation of lymphocytes into Th1 or Th2 cells is absolutely dependent upon the production of cytokines by APCs. For the purpose of this review, the term APCs will refer to macrophages and DCs, although B cells are also capable of presenting antigen. APCs are innate immune cells that are activated by microbial components via pattern-recognition receptors such as TLRs. Such triggering stimulates the secretion of a precise set of cytokines that ultimately results in a specific reaction against that pathogen by the induction of a Th1 or Th2 cell response. APCs thus bridge the innate and adaptive arms of immunity. It has been demonstrated that the APC-derived proteins IL-12 and IL-18 are key players in the development of a Th1 cell response and that they synergize with one another by upregulating their reciprocal receptors on the surface of Th1 cells (4, 5). Alternatively, Th2 cell differentiation seems to be promoted solely by T cell–derived cytokines, in particular IL-4, subsequent to interaction with APCs.

Until recently, the development of autoimmune diseases was also conceptualized as being governed by the Th1/Th2 subset model, whereby it was widely held that Th1 cells form the patho-

Nonstandard abbreviations used: AIA, antigen-induced arthritis; CIA, collagen-induced arthritis; CII, collagen type II; CSF, cerebrospinal fluid; GATA3, GATA-binding protein 3; IFN-γR, IFN-γ receptor; MOG, myelin oligodendrocyte glycoprotein; T-bet, T-box expressed in T cells.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:1119–1127 (2007). doi:10.1172/JCI31720.
paradigm mostly due to data describing autoimmune disease in results, autoimmunity has persisted to be defined by the Th1/Th2 Th1 cytokine deficiency thus presents a dichotomy, as it suggests produce IFN-γ of autoimmune disease (14). The disease-exacerbating effects of deletion of Th2 cytokines generally did not affect the progression of the animal model for RA (for a list of reports in support of the Th1/2 autoimmunity paradigm, see). Loss of IFN-γ–independent actions (28). The treatment of mice with recombinant IL-12 is capable of exacerbating EAE and CIA, which is again thought to result from enhanced activation of IFN-γ–producing T cells (29). Of significant importance, roles for Th1-inducing cytokines can also be determined from studies of human disease. In MS, patients demonstrate increased levels of IL-12 in serum (30), cerebrospinal fluid (CSF) (31), MS lesions, and PBMCs when compared with controls (32). It has also been shown that augmented IL-12 expression is representative of the degree of disability, as IL-12p40 mRNA is elevated in MS patients during the development of active lesions and immediately prior to relapses during relapsing-remitting MS (33). Likewise, IL-12 is present in the inflamed synovium of RA patients both in synovium-infiltrating macrophages and synovial lining cells (34, 35). Taken together, IFN-γ in autoimmunity, T-bet–deficient mice are resistant to the induction of several experimental autoimmune diseases, such as EAE, inflammatory bowel disease (IBS), and SLE (17–20). Protection from disease correlated with a skewing in the ratio of the Th1/Th2 response toward a more dominant Th2 environment that included significant upregulation of the Th2 cytokines IL-4, IL-5, and IL-10. Conversely, inhibition of GATA-binding protein 3 (GATA-3) expression reduces Th2 cytokine expression, thereby decreasing allergic airway inflammation and hyperresponsiveness (21). Such an imbalance in the Th1/Th2-inducing transcription factors has also been observed during human disease, as relapsing-remitting MS patients have an increased expression of T-bet in peripheral blood leukocytes during relapse (22). On the other hand, increased gene expression of GATA3 and reduced expression of T-bet have been demonstrated in the airways of patients with asthma (23, 24). In light of the above data (see Evidence for Th1 pathogenesis in autoimmunity), immune-modifying strategies for the treatment of autoimmune inflammation have focused on the concept of immune deviation (reviewed in ref. 25), whereby autogressive Th1 cells are deviated toward a Th2-polarized phenotype. Thus, while the Th1/Th2 paradigm of autoimmunity has been bombarded with conflicting data, the fact that T-bet–deficient mice, as well as mice deficient in APC-derived, Th1-inducing cytokines, are resistant to the induction of antigen-driven autoimmune diseases has held this paradigm firmly in place. We will now discuss the role of APC-derived cytokines and the paradigm shift regarding their function in autoimmune inflammation that was finally initiated by a number of key findings.

**IL-12 and IL-18: major commanders of Th1 polarization**

APC-derived cytokines constitute signal 3 of T cell activation, and critically, they determine the outcome of T cell differentiation, indicating that they play a significant role in governing immunity. Mice deficient in Th1-inducing cytokines, such as IL-12 and IL-18, have been shown to be completely resistant to EAE and demonstrated reduced incidence and severity during CIA, which was again concomitant with reduced Th1 cell development. In addition, the treatment of mice with neutralizing Abs against IL-12p40 effectively prevents disease induction and suppresses EAE in adoptive transfer recipients (26). In CIA, IL-12 Ab treatment reduced the severity of disease but not the incidence, an effect that was associated with reduced IFN-γ production by restimulated lymph node cells; decreased spontaneous TNF, IL-6, and IL-10 production by synovial cells ex vivo; and a reduction in total anti–collagen type II (anti-CII) Abs (27). Notably however, administration of anti-IL-12 Abs showed efficacy in IFN-γ–deficient mice, demonstrating IFN-γ–independent actions (28). The treatment of mice with recombinant IL-12 is capable of exacerbating EAE and CIA, which is again thought to result from enhanced activation of IFN-γ–producing T cells (29). Of significant importance, roles for Th1-inducing cytokines can also be determined from studies of human disease. In MS, patients demonstrate increased levels of IL-12 in serum (30), cerebrospinal fluid (CSF) (31), MS lesions, and PBMCs when compared with controls (32). It has also been shown that augmented IL-12 expression is representative of the degree of disability, as IL-12p40 mRNA is elevated in MS patients during the development of active lesions and immediately prior to relapses during relapsing-remitting MS (33). Likewise, IL-12 is present in the inflamed synovium of RA patients both in synovium-infiltrating macrophages and synovial lining cells (34, 35). Taken together,
Evidence for Th1 pathogenesis in autoimmunity

**Th1 cytokines in autoimmune disease**

| IL-12 demonstrated in plasma, CSF, PBMCs, and plaques of MS patients (30–33, 98–100) |
| Higher percentage of IL-12Rβ1- and IL-12Rβ2-expressing T cells in CSF compared with blood of MS patients (101) |
| IFN-γ and IL-12 in synovial fluid monocytes compared with PBMCs of both RA patients and healthy controls (102) |
| Strong expression of IL-12p40 and IL-12p70 in synovial tissue of RA patients (34) |
| IL-18 expression in serum, PBMCs, and demyelinating lesions of MS patients (103–105) |
| IL-18 expression in synovial tissues of RA patients (106, 107) |
| Synovial IL-18 expression correlates directly with RA disease activity and response to disease therapy (108) |
| Serum levels of IFN-γ in RR-MS patients prior to onset of relapse (109) |
| Significant positive correlation between IFN-γ-producing PBMCs and MS disability (110) |
| IL-12, IL-2, IFN-γ, TNF-α, IL-1β, and IL-6 in PBMCs of patients with acute and relapsing MS (100) |

**Th1 cytokines in experimental autoimmune disease**

- Anti–IL-12p40 Abs reduced CIA severity but not incidence associated with ↓ IFN-γ levels (27)
- Anti–IL-12p40 Ab suppresses EAE in adoptive transfer recipients (26)
- IL-12p40-deficient mice are resistant to MBP-induced EAE (28)
- IL-12 treatment increases development of IFN-γ-producing CD4+ T cells and thus increases the severity of CIA (29)
- Anti–IL-18 Abs significantly ↓ IFN-γ production and disease development during MBP-induced EAE in rats (111)
- IL-12-deficient mice are resistant to MOG35–55-induced EAE due to decreased IFN-γ production (71)
- ↓ Incidence and severity of CIA in IL-18-deficient mice (72)
- ↓ CIA severity in mice treated with anti–IL-18 Ab or rhIL-18BP (112)
- CNS-infiltrating cells of EAE mice stained for IFN-γ and IL-2 (8)
- CD4+ T cells infiltrating the CNS of acute EAE mice produced the Th1 cytokines IL-2 and IFN-γ (7)
- T-bet–deficient mice completely failed to generate Th1 cells and thus are resistant to MOG35–55-induced EAE (17)

| MBP, myelin basic protein; rhIL-18BP, recombinant human IL-18 binding protein; RR-MS, relapsing-remitting MS. ↑, increased; ↓, decrease(d). |

**A case of mistaken identity?**

IL-12 is a heterodimeric cytokine of approximately 70 kDa consisting of heavy (i.e., p40) and light (i.e., p35) subunits, which are covalently linked through disulfide bonds. While p40 appears to be produced in abundance in IL-12–expressing cells, p35 is ubiquitously and constitutively expressed only at low levels, and it requires p40 coexpression for secretion of the biologically active cytokine from the cell. The wealth of data pertaining to IL-12’s role in autoimmunity originated from studies using mice deficient in the p40 subunit of IL-12 as well as the administration of Abs that turned out to be specific for IL-12p40, both of which abolish expression and/or the function of IL-12. However, a series of reports has led to a revised concept of IL-12 function in autoimmune disease, starting in 2000 with further evidence that the p40 subunit is able to dimerize with subunits other than p35 (36). While it was previously known that p40 could homodimerize to form p80 with putative IL-12 antagonistic activities (37), Oppmann and colleagues identified an IL-6/IL-12-related subunit, p19, with which p40 heterodimerizes to form the cytokine IL-23 (36). Upon ubiquitous transgenic expression of p19 in mice, Wiekowski et al. showed that p19 has biological properties similar to those of IL-6, G-CSF, and IL-12, which resulted in the induction of multiorgan inflammation in these animals (38). In 2002, we were able to demonstrate that immunized mice deficient in IL-12p35 were surprisingly not resistant to myelin oligodendrocyte glycoprotein–induced (MOG-induced) EAE but actually had increased clinical severity, a finding that was reproduced by others (39, 40). Interestingly, the conflicting phenotypes were accompanied by a decrease in Th1 immunity in both disease-susceptible p35-deficient mice and disease-resistant p40-deficient mice (39). In addition, mice lacking the p40-binding receptor subunit of IL-12—IL-12Rβ1—were also resistant to EAE, but the p35-binding subunit, IL-12Rβ2, was shown to be unnecessary (41). The discordant effects of IL-12p40 and IL-12p35 clearly suggest an indispensable role for p40 but not for IL-12 in experimental disease. The incompatibility of the p40 and p35 phenotypes seemed likely to result from the promiscuity of the p40 subunit, whereby resistance of p40-deficient mice resulted from
the lack of IL-23 and not IL-12. This was later confirmed in mice lacking IL-23 and not IL-12. This was later confirmed in mice

IL-23 is secreted by APCs and signals via the high-affinity receptor complex IL-23R, which is made up of the p40-binding IL-12Rβ1 subunit and the signaling IL-23R subunit. IL-23R is present on the surface of various cells of the immune system, including activated/memory T cells, NK cells, DCs, monocytes, and macrophages. In contrast to IL-12R, IL-23R is highly expressed on murine memory CD4+ T cells and is expressed at low levels on naive T cells, permitting unique effects of IL-23 on this cell type. As demonstrated in p19−/− mice, IL-23 does not affect Th1 polarization, as evidenced by an intact IFN-γ response (44). In contrast, IL-23 is one of the factors essential for the expansion and survival of another, newly defined Th cell subset that secretes IL-17 and is consequently known as the Th17 subset.

**Th17 cells**

After the discovery of a new Th cell subset by Langrish et al. (44), a large number of articles in short succession were dedicated to the regulation of IL-17 expression by such Th17 cells. IL-17 (also known as IL-17A) is a proinflammatory cytokine that induces the expression of IL-1, IL-6, G-CSF, as well as chemokines, by cells such as fibroblasts, stromal cells, and endothelial cells (45–51). It is secreted by CD4+ Th17 cells, which characteristically also produce IL-17F (another IL-17 family member, with the closest sequence identity to IL-17A), IL-6, TNF-α (44, 52), and IL-22 (53–55). Indeed, this Th17 subset is now considered to constitute the critical population responsible for mediating pathogenesis during autoimmunity. The expression of IL-17 has been associated with numerous human autoimmune diseases, such as RA (56, 57) and MS (58, 59), and its inhibition or deletion in the corresponding animal models has provided a varying degree of protection (44, 60–63). A delicate balance of cytokines promotes the differentiation of naive CD4+ T cells into either polarized Th17 cells or autoimmune-suppressing Tregs. While TGF-β stimulates polarization of CD4+ T cells into Tregs in the absence of IL-6 in vitro, the additional presence of IL-6 evidently shifts the balance toward the proinflammatory Th17 phenotype, a process that is amplified by IL-1β and is negatively regulated by Th1 and Th2 cytokines (43, 63–65) (Figure 2). Both in vitro and in vivo differentiation of Th17 cells require induction of the transcription factor retinoic acid–related orphan receptor-γt (RORγt), which is characteristic of this new T cell subset (66). In light of this emerging T cell subset, some of the previously observed discrepancies in the Th1/Th2 paradigm of autoimmunity could be explained, especially with regard to the conflicting data obtained for IL-12p40– and IL-12p35–deficient mice. Lymphocytes obtained from EAE-resistant IL-12p40−/− and IL-12p35−/− mice demonstrate defects in both Th1 and Th17 responses, while cells from hypersusceptible IL-12p35−/− mice, which still express IL-23, lack Th1 development but have an elevated frequency of Th17 cells (67, 68). Consistent with these findings, EAE-resistant IL-23p19−/− mice show normal Th1 responses but have significantly reduced IL-17 production (44). Adoptive transfer experiments showed that encephalitogenic CD4+ T cells that had been treated in vitro with antigen and IL-23, but not IL-12, could induce EAE in recipient mice (44). In accordance with a role for IL-23 in the expansion and survival of Th17 cells, IL-23 has been demonstrated to be required during the effector phase of EAE (42, 69) (Figure 2). The generation of bone marrow chimeric mice, in which p40 was expressed either in the CNS or the peripheral immune system, showed that p40 is not absolutely required for the infiltration of inflammatory cells into the CNS but that p40 produced by cells resident to the CNS is essential for maintaining encephalitogenicity of T cell migration into the CNS (69). Furthermore, Cua et al. showed that injection of IL-23 into the CNS of p19−/− mice abrogated resistance of these animals to EAE (42). They suggest that the role of IL-23 in promoting encephalitogenicity results from its activation of macrophages present in the inflamed CNS to produce proinflammatory cytokines such as IL-1 and TNF. This points to an important role for IL-23 in the regulation of myeloid cells in organ-specific autoimmune diseases. However, the precise action of IL-23 in autoimmunity apart from its direct effect on Th cells still needs to be elucidated.

The above findings with regard to IL-12 and IL-23 in the context of CNS autoimmune inflammation were also reproduced in the animal model of autoimmune joint inflammation (i.e., CIA) (43, 70). Mice lacking IL-23 are resistant to disease induction and show no pathology upon histological examination of the joints. IL-12p35−/− mice, however, have an enhanced CIA severity and a delayed disease recovery in comparison with WT mice, although...
there is no difference at the histopathological level (43). IL-23 or IL-12 deficiency did not affect arthritis development at the level of CII-specific T cell proliferation; however, gene expression analysis demonstrated a decrease in IFN-γ and an increase in IL-1β, IL-6, IL-17, TNF, and nitric oxide synthase 2 in the absence of IL-12. Despite the increased levels of IFN-γ, there was no difference in the expression of IFN-γ–associated chemokines in the joints of IL-12−/− mice. Therefore, IL-23 and not IL-12 is required for mediating the pathogenesis of autoimmune joint inflammation, which is subsequently, to some extent, modulated by the IL-12/IFN-γ pathway (for a list of reports rejecting the Th1/Th2 paradigm, see Evidence for Th17 pathogenesis in autoimmunity).

**IL-18: another Th1 inducer lost to autoimmune pathology**

The evidence discussed above clearly argues against a role for IFN-γ–secreting Th1 cells in the pathogenesis of autoimmune disease and suggests a more regulatory role for this subset (Evidence for Th17 pathogenesis in autoimmunity). However, given the known actions of IL-18, as well as the previously discussed role of T-bet, this paradigm cannot be completely dismissed. IL-18 is an 18-kDa proinflammatory cytokine and a member of the IL-1 superfamily of cytokines, although its activities are more similar to those of IL-12. It is, like IL-12, expressed by macrophages and DCs but also by epithelial cells, keratinocytes, and other stromal cells. It signals through the IL-18R, a heterodimeric complex of an IL-18Rα–binding subunit and an IL-18Rβ signaling subunit (also termed IL-1RAcPL or IL-1R7). The extracellular portion of IL-18Rα is responsible for IL-18 binding. However, this requires the presence of the receptor β subunit, which comprises the high-affinity receptor complex. IL-18Rβ is expressed by a variety of immune cells, including lymphocytes, NK cells, macrophages, and neutrophils. As a result, IL-18 has pleiotropic effects, although it is best known for its promotion of Th1 differentiation and IFN-γ production through its synergistic activities with IL-12 (Figure 2). It can also independently stimulate the cytotoxic activities of NK cells. It has previously been shown that IL-18−/− mice are protected from MOG35-55–induced EAE and are unable to mount autoreactive Th1 responses (71). The defective Th1 cell response was suggested to result at least in part from abrogated IFN-γ production by NK cells, as transfer of NK cells from RAG-deficient, but not from IFN-γ−/−, mice was able to rescue the susceptibility of these mice to EAE. In CIA, IL-18 deficiency reduced disease severity and incidence, characterized by decreased TNF-α in serum and spleen cultures and suppressed CII-specific Th1 responses (72). Administration of recombinant IL-18 to mice with CIA significantly enhances disease, with increased synovial hyperplasia, cellular infiltration, and cartilage erosion being observed (73). The effects of IL-18 are of a proinflammatory nature, as a significant increase in the production of IFN-β, TNF-α, and IL-6 occurred in these mice (74). The effects of IL-18 on bone and cartilage remain controversial, as both stimulatory and inhibitory effects on osteoclast formation have been reported (75–77). In contrast, a role for Th17 cells and Th17-mediated osteoclastogenesis in inducing autoimmune arthritis–related bone destruction has recently been established (78).

The discovery that IL-12 is superfluous during autoimmune pathogenesis while IL-18 is an absolute necessity raised the question of whether there is redundancy in the system whereby IL-18 can function in the absence of IL-12 to induce autoimmunity. We recently were able to show that this was not the case, as mice deficient in both IL-12p35 and IL-18 were still fully susceptible to MOG peptide–induced EAE (79). On further analysis, and in contrast to the previous report, we discovered that IL-18–deficient mice were fully susceptible to EAE. Furthermore, IL-18−/− mice produced T cell responses and IFN-γ levels that were identical to those of WT mice. Despite a clear contradiction between our findings and those of Shi et al. (71, 79), this was not the first time that a redundant role for IL-18 has been described in a model of autoimmune disease. Santos et al. used a model of autoimmune arthritis

---

**Evidence for Th17 pathogenesis in autoimmunity**

- IL-12p35−/− mice are susceptible to EAE (39, 40)
- IL-23−/− mice are resistant to EAE (42)
- IL-12p35−/− mice are susceptible to CIA, while IL-12p40−/− and IL-23p19−/− mice are protected from CIA (43)
- IL-18−/− mice are susceptible to EAE, EAU, and AIA (79–81)
- IFN-γ−/− mice are hypersusceptible to EAE (11, 13)
- IFN-γ−/− and IFN-γR−/− deficient mice are hypersusceptible to CIA (113–115)
- TNF-α−/− mice are not resistant to EAE (12)
- IL-4−/− mice are not hypersusceptible to EAE (14)
- IL-23 induces a population of encephalitogenic CD4+ T cells called Th17 cells (44)
- IL-17 block or deficiency reduces susceptibility to EAE and CIA (44, 60, 61, 63)
- IL-1 is necessary for the generation of Th17 cells (92)
- IL-18R is necessary for the generation of Th17 cells (79)
- IL-17 mRNA is augmented in blood and CSF mononuclear cells of MS patients (58)
- IL-17 is produced by the rheumatoid synovium (56)

EAU, experimental autoimmune uveoretinitis.

known an antigen-induced arthritis (AIA) that is induced with methylated BSA in CFA and, in contrast to CIA, is dependent on cell-mediated immunity only (80). Applying this model, they were able to show that IL-18 is not required for AIA, nor is it necessary as a Th1 response cofactor and inflammatory cytokine (80). The conflicting results described for IL-18 in EAE and AIA models have been postulated to result from several possible causes. Differences in backcrossing or the health status of the mouse are likely to be the main reasons, while, in the arthritis model, variability may have resulted from the divergent pathogenic mechanisms of these models. However, genetic background of the mice may also play a role. While IL-18−/− mice were backcrossed to the arthritis-susceptible DBA/1 background for CIA induction, AIA experiments were performed in IL-18−/− mice backcrossed onto the C56BL/6 background. Speaking against this hypothesis is the demonstration that IL-18−/− mice on a DBA/1 background are not protected from ocular experimental autoimmune uveoretinitis (EAU), an autoimmune disease targeting photoreceptor antigens of the eye (81). It would nevertheless be of significant interest to determine the susceptibility of IL-18−/− mice to CIA that are not on the DBA background.

We felt that studying the susceptibility of IL-18Rα−/− mice to EAE could potentially shed light on the conflicting data discussed above. In contrast to the emerging nonpathogenic role for IL-18 in autoimmunity, which is in line with the changing Th1/Th2 paradigm, we discovered that IL-18Rα deletion induces resistance to EAE development (79). The administration of anti–IL-18R Abs to IL-18−/− mice abrogated disease development both before and after disease onset, leading us to conclude that an alternative ligand exists that is capable of binding to and signaling through IL-18Rα to induce autoimmunity. Finally, IL-18Rα−/− mice failed to generate and/or sustain encephalitogenic Th17 cells. In this context, we discovered that IL-18Rα engagement on accessory cells, and not lymphocytes, results in defective IL-12/23p40 production.

In light of the fact that the affinity of IL-18 to IL-18Rα is weak (82) and that there are still a number of orphan ligands in the IL-1 superfamily, we propose that an unknown alternative ligand binds to IL-18Rα and a so-far-unidentified signaling subunit expressed on APCs. Engagement of the IL-18Rα by this ligand supports the production of IL-23 necessary for the consequent expansion of Th17 cells.

Strengthening the findings that IL-18Rα is capable of interacting with a ligand other than IL-18, Lewis and Dinarello recently showed opposite responses in the rejection of IL-18−/− and IL-18Rα−/− pancreatic islets (83), which led the authors to propose the existence of an IL-18−/−dependent inhibitory pathway that converges with the proinflammatory IL-18 signaling pathway at the IL-18R. Furthermore, they suggest the involvement of IL-1F7, a member of the IL-1 family that binds IL-18 binding protein (IL-18BP) and IL-18Rα, thereby inhibiting IL-18 activity.

Taken together, the data indicate that the polarization of Th17 cells clearly correlates with pathogenicity, while APC-derived cytokines have a critical role in polarizing Th cells toward this autoimmune phenotypic characteristic (84). Thus, it would be of interest to reassess the role of the Th17-inducing cytokines IL-1, IL-6, and TGF-β in autoimmunity. It has long been known that both IL-1 and IL-6 are present in the synovial fluid of RA patients (85, 86), whereas in MS, IL-6 was upregulated in the plasma and CSF of MS patients, although no correlation between IL-6 levels and disease activity could be made (87). Correspondingly, IL-6−/− mice are protected from EAE and have delayed onset and reduced severity of CIA (88, 89). IL-1−/− mice are resistant to CIA, and IL-1R−/− mice are protected from EAE (90, 91). However, as IL-17 itself stimulates the production of both these molecules, this begs the question whether these in vitro Th17-inducing cytokines act upstream or downstream of IL-17. With regard to IL-1, Sutton et al. have provided evidence pointing to an upstream role for IL-1 (92). They showed that EAE resistance of IL-1R−/− mice results from deficient IL-17 production and that the adaptive transfer of encephalitogenic T cells can induce EAE in these mice (92). Furthermore, the spontaneous development of autoimmune arthritis in IL-1R antagonist–deficient (IL-1Rα−deficient) mice was completely prevented in mice on an IL-17−deficient background (93). Together, these data suggest that IL-1 is required for EAE during the development but not during the effector stages through its induction of Th17 cells. With regard to IL-6, Hirota et al. have demonstrated that the spontaneous occurrence of autoimmune arthritis in SKG mice results from Th17 cell development, but only in the presence of IL-6 (94). Therefore, IL-6 also appears to act upstream of Th17 cells. Adding complexity to the Th17 pathway is the recent discovery that IL-25, also known as IL-17E and a member of the IL-17 family of cytokines, can regulate Th17 function in autoimmune inflammation (95). IL-25−/− mice are hypersusceptible to EAE as a result of increased IL-23 expression and a subsequent increase in the number of Th17 cells. The effects of IL-25 were mediated through elevation of IL-13, which in turn inhibits IL-23, IL-1β, and IL-6 expression in activated DCs (95).

Concluding remarks

While the Th1/2 paradigm has for more than a decade served to conceptually encompass the role and function of Th cells in autoimmune disease, it has not withstood the recent developments in molecular biological techniques that have permitted the ultimate testing of the hypothesis using gene-targeted animals. Initial findings that Th1-deficient mice are still susceptible or even hypersusceptible to autoimmune disease proved conflicting until the discovery that APC-derived, Th1-polarizing cytokines are also redundant during autoimmune pathogenesis. The remaining inconsistency preventing the complete disintegration of the Th1/Th2 paradigm is the evidence that mice deficient in the Th1 transcription factor T-bet are resistant to EAE. However, it is feasible that resistance to autoimmune disease in T-bet−deficient systems is the result of mechanisms other than the inability of CD4+ T cells to differentiate into Th1 cells: T-bet has been shown to be essential for optimal selectin ligand expression in Th1 cells and their subsequent trafficking (96, 97); significantly upregulated levels of IL-10 have been demonstrated in T-bet−/− mice, indicating a possible increase in and effect of immunoregulatory Tregs (18); a comparison of WT CD4+CD25+ T cells and T-bet−/− CD4+CD25− cells showed that T-bet−/− cells had an enhanced ability to suppress proliferation of WT CD4+CD25+ and T-bet−/− CD4+CD25+ effectors (17). Furthermore, it has been suggested that T-bet may play a role in Th17 responsiveness during T cell differentiation (68).

Despite the somewhat conclusive evidence indicating a pathogenic role for Th17 cells, anti–IL-17 Ab treatment (44, 63) or IL-17 deficiency (60) in mice does not yield complete resistance to autoimmune disease in contrast to deficiency in IL-23 (42, 43) or factors promoting IL-23 such as IL-18Rα (79). This suggests a more complex network downstream of IL-23 signaling, involving factors in addition to IL-17. It has recently been demonstrated that Th17...
cells concomitantly produce IL-22, whose expression is controlled by the same IL-17–promoting cytokines (53, 54). IL-22 has been demonstrated to have a pathogenic role in psoriasis (55), but it remains to be shown whether this cytokine is important in other autoimmune inflammatory diseases. Therefore, there are likely other as-yet-unidentified factors either upregulated or suppressed by IL-23. Last, the dominant role of IL-23 may not only be related to its impact on pathogenic T cells. Accessory cells such as macrophages and DCs also express the receptor of IL-23, and its impact on disease is yet to be fully elucidated. The evidence against the Th1/Th2 paradigm of autoimmunity and in support of IL-23/IL-17–mediated mechanisms is overwhelming and demonstrates an indispensable role for APC-derived cytokines in promoting and/or suppressing autoimmune disease. The recent observations that IL-18 and IL-18Rα produce different effects in autoimmune disease (79, 83) demonstrate the complexity of the system and suggest that in addition to unknown T cell factors, additional APC-derived cytokines are secreted and necessary for T cell differentiation and autoimmune disease pathogenesis.

Address correspondence to: Burkhard Becher, Neuroimmunology Unit, Neurology Clinic, University of Zurich, Y44 J7 Winterthurerstrasse 190, Zurich 8057, Switzerland. Phone: 41-44-635-3703; Fax: 41-44-635-6883; E-mail: Burkhard.Becher@neuroim.unizh.ch.

Immunity.


46. Fossiez, F., et al. 1996. T cell interleukin-17 induces atrial cells to produce proinflammatory and hemo-

47. Jovanovic, D.V., et al. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human mac-


49. Aggarwal, S., and Gurney, A.L. 2002. IL-17: pro-


54. Harrington, L.E., et al. 2005. Interleukin-17 pro-


